⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Apelin
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-26 — Hormonal dimorphism in sarcopenia disease.: Narrative review (no new primary data) frames apelin as a female-predominant sarcopenia axis disrupted by menopausal estrogen loss, arguing for sex-stratified therapy alongside insulin and oxytocin pathways. [mechanism-plausible] (novelty: 3)
Open questions
Related
Contributing findings
Hormonal dimorphism in sarcopenia disease.
26-jun-2026
novelty 3
per-area 3
strengthens